243 related articles for article (PubMed ID: 32111660)
21. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
22.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
23. Establishing
Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
25. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
26. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
27. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
28. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
Sutherland DEK; Azad AA; Murphy DG; Eapen RS; Kostos L; Hofman MS
Semin Nucl Med; 2024 Jan; 54(1):4-13. PubMed ID: 37400321
[TBL] [Abstract][Full Text] [Related]
29. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
30. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
31. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
Adnan A; Basu S
PET Clin; 2022 Oct; 17(4):641-652. PubMed ID: 36153234
[TBL] [Abstract][Full Text] [Related]
32. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
[TBL] [Abstract][Full Text] [Related]
34. 177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
Has Simsek D; Civan C; Ekenel M; Kuyumcu S; Sanli Y
Clin Nucl Med; 2021 May; 46(5):415-418. PubMed ID: 33630811
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of prostate-specific membrane antigen expression in locally advanced or metastatic breast carcinoma with 68 Ga-PSMA-11 positron-emission tomography/computed tomography imaging for potential theranostics.
Parghane RV; Suralkar T; Nikam D; Basu S
Nucl Med Commun; 2024 Apr; 45(4):329-337. PubMed ID: 38312049
[TBL] [Abstract][Full Text] [Related]
36. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
37. 68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
Schollhammer R; de Clermont Gallerande H; Robert G; Yacoub M; Vimont D; Hindié E; Fernandez P; Morgat C
Clin Nucl Med; 2019 Sep; 44(9):e535-e536. PubMed ID: 31246685
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
[TBL] [Abstract][Full Text] [Related]
39. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
[TBL] [Abstract][Full Text] [Related]
40. Letter to the editor: Combined [
Duarte PS
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):642-643. PubMed ID: 36258051
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
